ARQT

Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc. (ARQT) has 17 SEC Form 4 filings (22 transaction rows) in the rolling window, disclosed by 6 distinct insiders. Most recent filing: Jun 18, 2026.

The most active filer is Director Welgus Howard G. with 3 filings. Insiders have net sold $730K over the trailing 6 months.

  • Industry:Biotechnology
  • CEO:Todd Franklin Watanabe
  • Employees:342
  • HQ:Westlake Village, CA, US
  • IPO:2020-01-31

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$730K

reported sales (SEC code S)

Unique Insiders

6

in the rolling window

Market Cap

$3.5B

latest known value

Source
LIN SUE-JEANFirst filing
Sale$121KJun 18SEC ↗
Sale$100KJun 18SEC ↗
Sale$16KJun 18SEC ↗
Sale$9KMay 13SEC ↗
Sale$5KMay 13SEC ↗
Matsuda MasaruFirst filing
Sale$192KMay 6SEC ↗
Burnett PatrickFirst filing
Sale$16KMay 6SEC ↗
Vairavan LathaFirst filing
Sale$32KMay 6SEC ↗
Watanabe ToddFirst filing
Sale$75KMay 6SEC ↗
Welgus Howard G.First filing
Sale$164KMay 6SEC ↗

Congress trading ARQT

See timeline →
  • DRep. Gilbert CisnerosPurchase$1,001 - $15,0002026-05-29

STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.

Related companies

Arcutis Biotherapeutics, Inc. is in the Healthcare sector.